Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity.
cyclophosphamide
monoclonal antibody
multiple tolerization subtractive immunization
surface-epitope masking
tumor biomarkers.
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
08
2021
accepted:
17
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
19
2
2022
Statut:
epublish
Résumé
Monoclonal antibodies (mAbs) have been a valuable tool to elucidate several biological processes, such as stem cell differentiation and cancer, and contributed to virtually all areas of biomedical sciences. Yet, it remains a challenge to obtain mAbs specific to poorly expressed epitopes, or to epitopes that are actually involved in important biological phenomena, such as cell differentiation and metastasis. Drug-induced subtractive immunization, and recently the multiple tolerization subtractive immunization (MTSI) technique, reported by our group, have the potential to level up the field, as they direct the host´s immune response towards these epitopes. However, due to cyclophosphamide (CY) treatment, high mice mortality can be observed, and only a few data are available on how these techniques affect the immune system of mice. Tolerogen and immunogen cells, RWPE-1 and PC-3 cells, respectively, were individually seeded at 2 × 10
Identifiants
pubmed: 34950138
doi: 10.3389/fimmu.2021.760817
pmc: PMC8688850
doi:
Substances chimiques
Antibodies, Monoclonal
0
Epitopes
0
Immunosuppressive Agents
0
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
760817Informations de copyright
Copyright © 2021 de Lima Fontes, Neves, Santos, Fusco-Almeida, Giannini, Felisbino, Deffune and Moroz.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Pharmacol Ther. 2017 Sep;177:129-145
pubmed: 28315359
Nat Clin Pract Oncol. 2008 Oct;5(10):588-99
pubmed: 18695711
MAbs. 2019 Feb/Mar;11(2):219-238
pubmed: 30516432
Biotechniques. 1992 Jun;12(6):842-7
pubmed: 1642892
Endocr Relat Cancer. 2004 Dec;11(4):659-87
pubmed: 15613445
Exp Hematol. 2002 May;30(5):440-9
pubmed: 12031650
J Clin Med. 2019 Jul 24;8(8):
pubmed: 31344926
Curr Opin Pharmacol. 2008 Oct;8(5):627-31
pubmed: 18804182
Biochem Biophys Res Commun. 2003 Apr 11;303(3):733-44
pubmed: 12670472
Cell Tissue Res. 2008 Aug;333(2):197-206
pubmed: 18560898
Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6
pubmed: 25568796
J Immunol Methods. 1987 Jun 26;100(1-2):73-82
pubmed: 3598198
Toxicology. 2006 May 1;222(1-2):60-70
pubmed: 16517039
Comp Med. 2015 Apr;65(2):96-113
pubmed: 25926395
Immunopharmacology. 1988 Jan-Feb;15(1):21-30
pubmed: 3258856
Monoclon Antib Immunodiagn Immunother. 2018 Apr;37(2):100-104
pubmed: 29708868
Nat Rev Cancer. 2015 Jun;15(6):361-70
pubmed: 25998715
Oncogene. 2003 Mar 27;22(12):1783-94
pubmed: 12660814
Expert Opin Drug Discov. 2018 Aug;13(8):685-690
pubmed: 29792354
Theranostics. 2020 Jan 1;10(2):938-955
pubmed: 31903161
J Cell Biol. 1993 Sep;122(6):1351-9
pubmed: 8376467
Methods Mol Biol. 2007;383:245-58
pubmed: 18217690
Cancer Res. 1986 Oct;46(10):5029-34
pubmed: 3463409
Microbiol Res. 2015 Feb;171:97-106
pubmed: 25553830
MAbs. 2018 Jan;10(1):46-54
pubmed: 28581886